白蛋白结合型紫杉醇联合顺铂治疗晚期非小细胞肺癌的临床效果

目的 探讨白蛋白结合型紫杉醇联合顺铂治疗晚期非小细胞肺癌(NSCLC)的临床效果.方法 选取2019年12月至2020年12月我院收治的56例晚期NSCLC患者作为研究对象,将其随机分为对照组和研究组,各28例.对照组采用吉西他滨联合顺铂治疗,研究组采用白蛋白结合型紫杉醇联合顺铂治疗.比较两组的临床疗效、血清肿瘤标志物...

Clinical effect of albumin-bound paclitaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer

Objective To investigate the clinical effect of albumin-bound paclitaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 56 patients with advanced NSCLC treated in our hospital from December 2019 to December 2020 were selected as the study objects and randomly divided into control group and study group,with 28 cases in each group.The control group was treated with gemcitabine combined with cisplatin,and the study group was treated with albumin-bound paclitaxel combined with cisplatin.The clinical efficacy,the levels of serum tumor markers and the occurrence of toxic and side effect were compared between the two groups.Results The ORR of the study group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05);there was no significant difference in DCR between the two groups(P>0.05).Before treatment,there were no significant differences in the levels of CEA and CA125 between the two groups(P>0.05);after treatment,the levels of CEA and CA125 in the two group significantly decreased,and those in the study group were lower than the control group,the differences were statistically significant(P<0.05).The total incidence of toxic and side effect in the control group was 28.57%,and that in the study group was 17.86%,there was no significant difference between the groups(P>0.05).Conclusion Albumin-bound paclitaxel combined with cisplatin in the treatment of advanced NSCLC has significant effect.It can effectively reduce the levels of serum tumor markers,and without increasing toxic and side effect,which is worthy of clinical application and promotion.